(Rac)-Vazegepant-13C,d3

• UNSPSC Description:

  (Rac)-Vazegepant-13C,d3 is the C13 and deuterium labeled (Rac)-Vazegepant. Vazegepant (HY-134992) is the first intranasal CGRP receptor antagonist for the study the acute research of migraine[1][2].

• Target Antigen:

  Isotope-Labeled Compounds

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Others

• Field of Research:

  Others

• Solubility:

  10 mM in DMSO

• Smiles:

  CC1=C2NN=CC2=CC(CC(NC(N3CCC(C4=CC5=CC=CC=C5NC4=O)CC3)=O)C(N6CCN(C7CCN([13C]([2H])([2H])[2H])CC7)CC6)=O)=C1

• Molecular Weight:

  642.81

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.|[2]Leonard KA, et al. Discovery of a Gut-Restricted JAK Inhibitor for the Treatment of Inflammatory Bowel Disease. J Med Chem. 2020 Mar 26;63(6):2915-2929.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported